The new study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.
AbstractAims/hypothesisN-terminal pro-B-type natriuretic peptide (NT-proBNP) is the gold standard prognostic biomarker for diagnosis and occurrence of heart failure. Here, we compared its prognostic value for the occurrence of congestive heart failure with that of plasma mid-region pro-adrenomedullin (MR-proADM), a surrogate for adrenomedullin, a vasoactive peptide with vasodilator and natriuretic properties, in people with type 2 diabetes.MethodsPlasma MR-proADM concentration was measured in baseline samples of a hospital-based cohort of consecutively recruited participants with type 2 diabetes. Our primary endpoint was h…
ConclusionsThis study confirms the high prevalence of CKD in patients with multiple comorbidities: T2D and CVD. It also provides estimates of the prevalence of CKD categories based on KDIGO 2012 classification for US adults with T2D.
This study suggests that exocrine glands can be induced from pluripotent stem cells for organ replacement regenerative therapy.
Replacement of Aged Microglia Partially Reverses Cognitive Decline in Mice
Researchers here report on a compelling demonstration that shows the degree to which dysfunctional microglia contribute to age-related neurodegeneration. The scientists use a pharmacological approach to greatly deplete the microglial population and then allow it to recover naturally. The…
Researchers here report on a gene variant associated with reduced incidence of metabolic disease, type 2 diabetes, and heart disease. The mechanism of action is a reduced uptake of glucose (and thus calories) in the gut. The estimated effect size over decades of life based on the short term data gathered is large: a reduction of a third in mortality risk. That is sizable enough for me to think that the study needs replication before taking it at face value, but it is thought-provoking nonetheless.
One thing to consider while reading this paper is that gene variants of this nature may help to pin down the plausible s…
Heart problems that were “largely preventable” killed around 415,000 Americans in 2016, new data from the Centers for Disease Control and Prevention (CDC) says, highlighting the importance of proactive interventions.
Under its new Million Hearts campaign, which aims to prevent a million heart attacks and strokes by 2022, the CDC looked at 2016 data and identified approximately 2.2 million hospitalizations and 415,000 deaths caused by heart attacks, strokes, heart failure and related conditions that likely could have been avoided. The total number of deaths related to heart issues is even higher — in 2015,…
Diabetes, Obesity and Metabolism, EarlyView.
Findings suggest trial drugs may reduce chance of heart failure for diabetic patientsHopes have been raised that drugs being trialled to treat anaemia could also be used to aid recovery after a heart attack and help decrease the chance of future heart failure.Initial results suggest the drugs could be given to people with Type 2 diabetes immediately after a heart attack, according to research funded by the British Heart Foundation (BHF) and Diabetes UK.Continue reading…
A growing number of studies suggest that getting a handle on a few key risk factors can bring type 2 diabetes under control. Lowering blood sugar, for instance, reduces the risk of additional health problems, such as heart disease and stroke related to the disease.
But most of these studies have focused on studying one risk factor — like blood sugar, cholesterol or blood pressure — at a time. In a new study published in the New England Journal of Medicine, researchers analyzed what happens to death rates and other health problems when people control up to five known risk factors for type 2 diabetes.
The study …
ConclusionsIn patients with T2D and persistent microalbuminuria, u-KIM-1, but not u-NGAL, was an independent risk factor for decline in eGFR, CVE and all-cause mortality, and contributed significant discrimination for all-cause mortality, beyond traditional risk factors.
This result represents the first genetic evidence in a large cohort for the protective effect of PCSK9 inhibition on ischemic stroke and corroborates exploratory evidence from clinical trials. PCSK9 inhibition was not associated with variables other than those related to LDL (low-density lipoprotein) cholesterol, atherosclerosis, and type 2 diabetes mellitus, suggesting that other effects are either small or absent.